Literature DB >> 26538985

Menopausal hormone therapy and ovarian cancer.

Rod Baber1.   

Abstract

Entities:  

Year:  2015        PMID： 26538985      PMCID： PMC4604667          DOI： 10.4103/0976-7800.165587

Source DB:  PubMed          Journal:  J Midlife Health


× No keyword cloud information.
  9 in total

1.  Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.

Authors:  James V Lacey; Louise A Brinton; Michael F Leitzmann; Traci Mouw; Albert Hollenbeck; Arthur Schatzkin; Patricia Hartge
Journal:  J Natl Cancer Inst       Date:  2006-10-04       Impact factor: 13.506

2.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.

Authors:  Tomas Riman; Paul W Dickman; Staffan Nilsson; Nestor Correia; Hans Nordlinder; Cecilia M Magnusson; Elisabete Weiderpass; Ingemar R Persson
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

3.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

4.  Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis.

Authors:  P P Garg; K Kerlikowske; L Subak; D Grady
Journal:  Obstet Gynecol       Date:  1998-09       Impact factor: 7.661

5.  Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy.

Authors:  K Hunt; M Vessey; K McPherson; M Coleman
Journal:  Br J Obstet Gynaecol       Date:  1987-07

6.  Hormone therapy and ovarian cancer.

Authors:  Lina Steinrud Mørch; Ellen Løkkegaard; Anne Helms Andreasen; Susanne Krüger-Kjaer; Ojvind Lidegaard
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

Review 7.  Oncology in midlife and beyond.

Authors:  A Gompel; R J Baber; T J de Villiers; K-E Huang; R J Santen; D Shah; P Villaseca; S Shapiro
Journal:  Climacteric       Date:  2013-08-09       Impact factor: 3.005

8.  Ovarian cancer and hormone replacement therapy in the Million Women Study.

Authors:  Valerie Beral; Diana Bull; Jane Green; Gillian Reeves
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

9.  Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.

Authors:  V Beral; K Gaitskell; C Hermon; K Moser; G Reeves; R Peto
Journal:  Lancet       Date:  2015-02-13       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.